News & Updates
Filter by Specialty:
Tezepelumab cuts OCS use in OCS-dependent patients with severe asthma
Patients with severe asthma who were dependent on oral corticosteroid (OCS) were able to reduce their use of maintenance OCS after treatment with the monoclonal antibody tezepelumab, according to findings from the interim analysis of the phase IIIb WAYFINDER trial.
Tezepelumab cuts OCS use in OCS-dependent patients with severe asthma
15 Nov 2023Which factors predict recurrence of RA-related organizing pneumonia?
The recurrence rate of organizing pneumonia (OP) associated with rheumatoid arthritis (RA) is high, but OP does not appear to contribute to RA exacerbation, suggests a study. Several factors predicting OP recurrence have been identified, such as smoking and lower age at OP onset.
Which factors predict recurrence of RA-related organizing pneumonia?
14 Nov 2023Right heart thrombus with pulmonary embolism tied to poor survival, ICU admission
Clinical presentation is more severe and survival much lower among patients with right heart thrombus and pulmonary embolism, who also require more advanced therapies, compared with those without a concomitant pulmonary embolism, a study has found. Thrombus mobility and size contribute to the development of concomitant pulmonary embolism.
Right heart thrombus with pulmonary embolism tied to poor survival, ICU admission
11 Nov 2023Nodal staging before SBRT does not affect survival in early-stage NSCLC
Patients with early-stage nonsmall cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) have similar overall survival (OS) regardless of nodal staging, reports a study. In addition, use of SBRT has shown a steady increase over the study period.
Nodal staging before SBRT does not affect survival in early-stage NSCLC
09 Nov 2023COVID-19 ups risk of pulmonary fibrosis
Infection with COVID-19 may increase the risk of pulmonary fibrosis, and patients with a severe disease are at greater risk of developing this complication, suggests a recent study.
COVID-19 ups risk of pulmonary fibrosis
09 Nov 2023LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo
Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.